Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 20 Gastrointestinal 9 Head & Neck 5 Tumor-Agnostic 4 Genitourinary 2 Dermatologic 2 CNS 2 Breast 2 Sarcoma 1 Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 344 Rituximab 308 Vincristine 159 venetoclax 156 Doxorubicin 156 fludarabine 153 Specimen Handling 152 Prednisone 150 Biopsy 122 Magnetic Resonance Spectroscopy 117 obinutuzumab 116 Lenalidomide 109 Dexamethasone 106 Cytarabine 100 ibrutinib 96 Etoposide 94 fludarabine phosphate 87 Methotrexate 86 acalabrutinib 80 zanubrutinib 73 Bendamustine Hydrochloride 71 pembrolizumab 63 blinatumomab 63 CT-P10 61 Gemcitabine 52 glofitamab 45 Nivolumab 45 Calcium Dobesilate 45 prednylidene 43 Mercaptopurine 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Erlotinib Hydrochloride × Lymphoid × 1 year × Clear all

NCT03297606 2026-03-27

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡